Delivery of immunogens to mucosal immune system using an oral inactivated cholera vaccine

Azizi, Ali; Ghunaim, Haitham; Sirskyj, Danylo; Fallahi, Firouzeh; Le, Hoang Thanh; Kumar, Ashok

doi:10.4161/hv.24200

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, while the authors acknowledge that multiple vaccinations within a single influenza season may be difficult to implement, the advantages of oral immunisation are clear. These advantages include being less painful as they do not require administration using needle and syringe, greater degrees of compliance, ease and rapidity of administration -not requiring medically trained personnel to inject the vaccine and reducing the risk of needle stick infections [29]. Critically, oral vaccines prime mucosal immune responses, which can be of significant protective benefit at mucosal front line surfaces.…”

Section: Discussionmentioning

confidence: 97%

CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice

Mann

Tregoning

Aldon

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice

Mann

Tregoning

Aldon

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

“…As previously reported, the vaccine formulation design is focused on mucosal immunity. The core of this conjugate nicotine vaccine platform is composed of a bacterial-derived adjuvant (BDA) from either N. meningitides or V. cholerae and both have been used as part of effective human vaccines [11,12,[19][20][21][22]. The mucosal multiadjuvanted BDA is able to stimulate immune responses by activating antigen-presenting cells leading to effective adaptive immune responses [20], reviewed in [22].…”

Section: Discussionmentioning

confidence: 99%

Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine

et al. 2021

View full text Add to dashboard Cite

Tobacco smoking continues to be a global epidemic and the leading preventable cause of cancer and cardiovascular disease. Nicotine vaccines have been investigated as an alternative to currently available smoking cessation strategies as a means to increase rates of success and long-term abstinence. Recently, we demonstrated that a mucosal nicotine vaccine was able to induce robust mucosal and systemic antibodies when delivered heterologously using intranasal and intramuscular routes. Herein, we investigated the neutralization ability of the anti-nicotine antibodies using both intranasal and intracardiac nicotine challenges. Combining the extraction of lyophilized organ samples with RP-HPLC methods, we were able to recover between 47% and 56% of the nicotine administered from the blood, brain, heart, and lungs up to 10 min after challenge, suggesting that the interaction of the antibodies with nicotine forms a stable complex independently of the route of vaccination or challenge. Although both challenge routes can be used for assessing systemic antibodies, only the intranasal administration of nicotine, which is more physiologically similar to the inhalation of nicotine, permitted the crucial interaction of nicotine with the mucosal antibodies generated using the heterologous vaccination route. Notably, these results were obtained 6 months after the final vaccination, demonstrating stable mucosal and systemic antibody responses.

show abstract

Design of starch-formate compound fibers as encapsulation platform for biotherapeutics

Lancuški

Ammar

Avrahami

et al. 2017

Carbohydrate Polymers

View full text Add to dashboard Cite

Delivery of immunogens to mucosal immune system using an oral inactivated cholera vaccine

Cited by 4 publications

References 23 publications

CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice

CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice

Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine

Design of starch-formate compound fibers as encapsulation platform for biotherapeutics

Contact Info

Product

Resources

About